Rapid syndromic molecular testing in pneumonia: The current landscape and future potential - 15/01/20
, Tristan W. Clark bHighlights |
• | Syndromic molecular tests for pneumonia have greater sensitivity and detect many more pathogens than conventional culture. |
• | The greatest potential benefit of these tests is rapidly directed antibiotic use. |
• | Currently there are two commercially available syndromic molecular tests for pneumonia. |
• | No interventional trials have assessed the clinical impact of these tests and are urgently needed. |
Summary |
Community acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and ventilator associated pneumonia (VAP) are all associated with significant mortality and cause huge expense to health care services around the world. Early, appropriate antimicrobial therapy is crucial for effective treatment. Syndromic diagnostic testing using novel, rapid multiplexed molecular platforms represents a new opportunity for rapidly targeted antimicrobial therapy to improve patient outcomes and facilitate antibiotic stewardship. In this article we review the currently available testing platforms and discuss the potential benefits and pitfalls of rapid testing in pneumonia.
Le texte complet de cet article est disponible en PDF.Keywords : Pneumonia, Hospital acquired pneumonia (HAP), Ventilator associated pneumonia (VAP), Community acquired pneumonia (CAP), Molecular diagnostics, Rapid diagnostics, Point-of-care testing
Plan
Vol 80 - N° 1
P. 1-7 - janvier 2020 Retour au numéro
Article précédent
- Editorial Board
- Nanotechnology: A reality for diagnosis of HCV infectious disease
- Sonia Arca-Lafuente, Paula Martínez-Román, Irene Mate-Cano, Ricardo Madrid, Verónica Briz
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?